Succinylcholine Monograph: Pharmacology and Clinical Applications

Introduction

Definition and Overview

Succinylcholine, chemically known as (RS)-1,1-bis(2-hydroxyethyl)-2,2,3,3-tetrabutylazaniumyl‑1-(2‑hydroxyethyl)piperidinium chloride, is a synthetic, non‑depolarizing neuromuscular blocker that functions as a depolarizing agent. It is employed primarily as a rapid‑acting agent to facilitate tracheal intubation during general anesthesia and to provide muscle relaxation in emergency scenarios such as rapid sequence induction (RSI). The drug’s short duration of action, typically lasting 3–5 minutes, arises from its rapid hydrolysis by plasma cholinesterase, which differs from the metabolism of conventional non‑depolarizing agents.

Historical Background

Interest in depolarizing neuromuscular blockers emerged in the early 20th century with the discovery of curare derivatives. The synthesis of succinylcholine in 1943 by Dr. William Reeve and colleagues represented a pivotal advancement, offering a compound that could be administered as a single dose to achieve complete muscle paralysis in a predictable timeframe. Subsequent clinical studies throughout the mid‑20th century established its efficacy and safety profile, leading to widespread adoption in anesthetic practice.

Importance in Pharmacology and Medicine

Succinylcholine occupies a unique position in anesthetic pharmacology due to its distinctive mechanism of action, pharmacokinetic properties, and clinical utility. Its role in facilitating airway management, controlling skeletal muscle activity during surgeries, and providing rapid paralysis in life‑saving procedures underscores its relevance to both clinical pharmacology and perioperative medicine. Additionally, the drug’s interaction with other pharmacologic agents, its contraindications, and potential adverse effects present a rich array of educational opportunities for trainees.

Learning Objectives

• Identify the chemical structure, mechanism of action, and pharmacokinetic profile of succinylcholine.
• Explain the clinical indications, contraindications, and dosing considerations related to succinylcholine use.
• Recognize the potential adverse effects, including malignant hyperthermia, hyperkalemia, and prolonged paralysis.
• Apply knowledge of succinylcholine in the context of rapid sequence induction, intubation, and other perioperative scenarios.
• Critically assess patient-specific factors that influence succinylcholine selection and management.

Fundamental Principles

Core Concepts and Definitions

Succinylcholine is classified as a depolarizing neuromuscular blocking agent. Unlike non‑depolarizing blockers that competitively inhibit acetylcholine at nicotinic receptors, succinylcholine binds irreversibly to the nicotinic acetylcholine receptor (nAChR) at the motor endplate, causing an initial depolarization that is followed by desensitization and subsequent paralysis. The drug’s structural resemblance to acetylcholine facilitates its interaction with the receptor, yet its resistance to acetylcholinesterase-mediated hydrolysis is limited, leading to rapid inactivation by plasma cholinesterase (butyrylcholinesterase).

Theoretical Foundations

The pharmacodynamic effect of succinylcholine can be described by a two‑phase model: an initial phase of depolarization lasting a few seconds, followed by a phase of desensitization leading to muscle relaxation. The onset of action occurs within 30–60 seconds, and the duration of action is governed by the rate of hydrolysis. The relationship between plasma cholinesterase activity and drug clearance can be approximated by the equation:

C(t) = C₀ × e⁻ᵏᵗ

where C(t) is the plasma concentration at time t, C₀ is the initial concentration, and k is the elimination rate constant. The half‑life (t_1/2) of succinylcholine is typically 1–2 minutes in healthy individuals, but can be extended in cases of cholinesterase deficiency.

Key Terminology

• Depolarizing Neuromuscular Blocker: A compound that binds to nicotinic acetylcholine receptors and induces sustained depolarization, leading to paralysis.
• Plasma Cholinesterase: An enzyme responsible for the hydrolysis of succinylcholine; genetic polymorphisms can alter activity.
• Malignant Hyperthermia: A pharmacogenetic disorder triggered by depolarizing agents, characterized by hypermetabolism and elevated body temperature.
• Prolonged Paralysis: An extended duration of neuromuscular blockade beyond expected pharmacokinetics, often due to enzymatic deficiency.
• Rapid Sequence Induction (RSI): A technique that combines rapid drug administration with intubation to reduce aspiration risk.

Detailed Explanation

Mechanisms and Processes

Succinylcholine exerts its effect by mimicking acetylcholine and binding to the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. Following binding, the ion channel remains open, allowing Na⁺ influx and K⁺ efflux, resulting in depolarization of the muscle membrane. The sustained depolarization prevents subsequent repolarization, effectively halting the action potential and leading to flaccid paralysis. This desensitization phase is self‑terminating due to rapid hydrolysis of the drug by plasma cholinesterase, which limits the duration of blockade.

Pharmacokinetics

The absorption of succinylcholine occurs intravenously, providing immediate bioavailability. Distribution is rapid, with a volume of distribution approximating the extracellular fluid compartment (V_d ≈ 0.5 L/kg). The drug’s elimination is primarily via hydrolysis by plasma cholinesterase, yielding succinylmonocholine and succinyl‑2-hydroxyethylamine, both inactive. The clearance (Cl) can be calculated using the equation:

Cl = Dose ÷ AUC

where AUC represents the area under the plasma concentration–time curve. In normal physiology, the clearance of succinylcholine is high, yielding a short half‑life. However, in patients with cholinesterase deficiency, clearance is reduced, leading to prolonged action. Genetic polymorphisms such as the 176A>G mutation in the butyrylcholinesterase gene can significantly impact enzyme activity.

Mathematical Relationships

To estimate the duration of action, the following relationship is useful:

t_duration ≈ 3–5 × t_1/2

Given a typical t_1/2 of 1.5 minutes, the expected duration is approximately 4.5 minutes. This formula aids in anticipating recovery time for patients undergoing procedures requiring brief paralysis.

Factors Affecting the Process

1. Enzyme Activity: Variations in plasma cholinesterase levels, whether due to genetic factors, pregnancy, liver disease, or certain medications, directly influence drug clearance.
2. Age and Body Composition: Elderly patients may exhibit reduced enzyme activity, while obese individuals may have altered distribution volumes.
3. Drug Interactions: Agents that inhibit cholinesterase (e.g., aminoglycosides, organophosphates) can prolong succinylcholine effects. Conversely, cholinesterase inducers may accelerate metabolism.
4. Underlying Medical Conditions: Myasthenia gravis, burns, and neuromuscular disorders modify receptor dynamics and enzyme expression.
5. Genetic Polymorphisms: Single‑nucleotide polymorphisms in the butyrylcholinesterase gene alter enzyme kinetics, necessitating individualized dosing.

Clinical Significance

Relevance to Drug Therapy

Succinylcholine’s rapid onset and short duration make it indispensable for procedures requiring immediate, brief paralysis. Its use in RSI procedures minimizes the duration of airway manipulation, thereby reducing aspiration risk. Moreover, succinylcholine can serve as a diagnostic tool for evaluating neuromuscular function in certain contexts.

Practical Applications

Key clinical scenarios include:

• Intubation: Facilitates rapid tracheal intubation in emergent and elective settings.
• Electroconvulsive Therapy (ECT): Provides muscle relaxation during ECT to prevent musculoskeletal injury.
• Ventilator Support: Used in short‑term paralysis for ventilator weaning protocols.
• Diagnostic Studies: Employs intermittent dosing for neuromuscular monitoring.

Clinical Examples

During a surgical procedure requiring a brief period of muscle relaxation, a 68‑year‑old patient receives a 0.3 mg/kg dose of succinylcholine. The onset is within 45 seconds, and paralysis lasts approximately 4 minutes, allowing safe completion of the incision. No significant hyperkalemia or malignant hyperthermia is observed, given the patient’s normal cholinesterase activity.

Clinical Applications and Examples

Case Scenario 1: Rapid Sequence Induction in a Trauma Patient

A 35‑year‑old male presents to the emergency department with facial trauma and a suspected airway obstruction. Rapid sequence induction is planned. A dose of 1.5 mg/kg succinylcholine is administered intravenously. Intubation is achieved within 60 seconds, and muscle relaxation persists for 4 minutes, enabling definitive airway management. Post‑intubation, the patient is transferred to the intensive care unit for further stabilization.

Case Scenario 2: Malignant Hyperthermia Susceptibility

A 24‑year‑old female with a family history of malignant hyperthermia undergoes elective laparoscopic surgery. Succinycholine is avoided due to the genetic predisposition. Instead, a non‑depolarizing agent (e.g., rocuronium) is selected. This choice mitigates the risk of hyperthermic crisis, illustrating the necessity of individualized drug selection based on patient genetics.

Case Scenario 3: Prolonged Paralysis in Cholinesterase Deficiency

An 8‑year‑old child is admitted for cleft palate repair. During induction, a 0.3 mg/kg dose of succinylcholine is given. Unexpectedly, paralysis persists for 45 minutes. Subsequent evaluation reveals a homozygous mutation in the butyrylcholinesterase gene, confirming a deficiency. The patient is monitored until spontaneous recovery, and future anesthetic plans exclude succinylcholine.

Problem‑Solving Approach

1. Assessment of Enzyme Activity: Pre‑operative screening for cholinesterase deficiency via plasma cholinesterase levels or genetic testing.
2. Dose Individualization: Adjust dose based on patient weight, age, and comorbidities.
3. Monitoring: Continuous neuromuscular assessment using train‑of‑four (TOF) monitoring to gauge onset and recovery.
4. Emergency Preparedness: Availability of dantrolene and hyperventilation equipment to manage malignant hyperthermia.
5. Alternative Agents: Selection of non‑depolarizing neuromuscular blockers when succinylcholine is contraindicated.

Summary and Key Points

• Succinylcholine is a depolarizing neuromuscular blocker with rapid onset (≈30–60 s) and short duration (≈3–5 min).
• Its pharmacodynamic action involves sustained depolarization of the motor endplate leading to desensitization and paralysis.
• Hydrolysis by plasma cholinesterase determines clearance; genetic polymorphisms can prolong action.
• Clinical indications include rapid sequence induction, intubation, and short‑term paralysis during surgery.
• Contraindications encompass malignant hyperthermia susceptibility, severe hyperkalemia, and cholinesterase deficiency.
• Potential adverse effects: hyperkalemia, malignant hyperthermia, prolonged paralysis, bradycardia, and histamine release.
• Monitoring with train‑of‑four and readiness to treat malignant hyperthermia with dantrolene are essential.
• Dose calculations: typical 0.3–1.5 mg/kg IV; adjust for weight and clinical context.
• Clinical pearls: early identification of enzyme deficiency prevents prolonged paralysis; avoid succinylcholine in patients with burn injuries or neuromuscular disease.

Through a comprehensive understanding of succinylcholine’s pharmacology, clinical applications, and patient‑specific considerations, medical and pharmacy students can develop a robust foundation for safe and effective use of this critical neuromuscular blocker in perioperative and emergency settings.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.